YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by Y's Therapeutics, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Y's Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00876902
First received: April 3, 2009
Last updated: April 6, 2009
Last verified: April 2009
  Purpose

The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal vein and to the recipient intravenously prior to reperfusion. This study is an extension of the recent pilot study YSPSL-0002 with an almost identical study protocol. The rationale of this and the previous study is based on the recent observation that P-selectin expression has been associated in liver grafts with prolonged cold storage times and rejection. By examining biomarkers of IRI including P-selectin by immunohistochemistry and/or quantitative PCR, liver histology and hepatic blood flow using established techniques, the goal of this study is to evaluate the feasibility of using these modalities for future studies of safety and efficacy.


Condition Intervention Phase
Ischemia Reperfusion Injury
Drug: recombinant P-selectin glycoprotein ligand Ig fusion protein
Drug: Viaspan® and saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

Resource links provided by NLM:


Further study details as provided by Y's Therapeutics, Inc.:

Primary Outcome Measures:
  • Safety will be evaluated by clinical and laboratory assessments, an abbreviated pharmacokinetic (PK) profile of the administered dose of YSPSL, and graft function and patient and graft survival through 6 months post-transplant. [ Time Frame: 6 months post trasplant ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the potential efficacy of prophylaxis with YSPSL on ischemia reperfusion injury (IRI) as assessed by proposed efficacy evaluations of IRI in liver transplants, in patients who meet eligibility criteria for the trial. [ Time Frame: 6 months post transplant ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: May 2008
Estimated Study Completion Date: October 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
Drug: recombinant P-selectin glycoprotein ligand Ig fusion protein
The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
Other Names:
  • rPSGL-Ig
  • Torapsel
Placebo Comparator: 2
Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
Drug: Viaspan® and saline
Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
Other Name: Placebo

Detailed Description:

YSPSL-0003 is an extension into 36 patients of the previous 12 patient pilot study YSPSL-0002 under an almost identical study protocol with extended inclusion criteria. Like YSPSL-0002, YSPSL-0003 is a single-center (UCLA), randomized, placebo-controlled, double-blind study. Patients are randomly assigned to either active study drug (Active group) or placebo (Control group) prior to transplantation. The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses are administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Placebo of a volume equivalent to active study drug is prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, receive an additional 1 mg/kg IV infusion of study agent (or placebo equivalent) at the end of the transplant surgery. The Investigator/Sponsor is blinded to the treatment assignment for each patient. Randomization assignment is maintained by UCLA's clinical pharmacist.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient will be a recipient of a primary (first) ABO compatible cadaveric liver allograft
  • Patient's age is less than 18 years
  • Patient is not a recipient of a multivisceral transplant or simultaneous kidney transplant
  • Patient has not undergone prior organ or cellular transplant of any type
  • Patient has a Model for End Stage Liver Disease (MELD) score of ≤38
  • Cold ischemia time (CIT) anticipated to be less than 14 hours
  • Donor liver procured by UCLA liver team
  • Veno-veno bypass is not planned to be used for the patient (e.g. no prior surgery or other factor that indicates a risk for excessive blood loss and therefore a need for veno-veno bypass +/- autologous recovery during surgery)
  • For patients who are women of childbearing potential, patient has a negative pregnancy test (either urine or serum) within 48 hours prior to transplant
  • Patient (male and female) is willing to use an acceptable form of birth control for at least 3 months post-treatment
  • Patient is willing and able to sign informed consent.

Exclusion Criteria:

  • Patient has a prior organ transplant of any type
  • Patient has known allergic or intolerance reactions to human immune globulins, antibodies, or components of the formulation or known contraindication to administration of YSPSL
  • Patient has an uncontrolled active infection (on antibiotics with controlled infection is not an exclusion)
  • Patient has active Hepatitis B virus (HBV)/transplant for HBV related cirrhosis
  • Patient has previously participated in this study or another study with YSPSL
  • Patient has received investigational therapy within 90 days prior to the transplant procedure
  • Patient has current drug or alcohol abuse or, in the opinion of the investigator, is at risk for poor compliance with the visits in this protocol (no drug testing required)
  • Patient is a pregnant or nursing female, a female of childbearing potential planning to become pregnant within the duration of this study, or is not practicing birth control
  • Patient is planned to receive a living donor liver transplant
  • Patient lives >200 miles away or otherwise is not able to participate in study follow-up visits
  • Donor body mass index >40
  • Donor liver biopsy >40% macrosteatotic fat
  • Donor age >70.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00876902

Locations
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Y's Therapeutics, Inc.
Investigators
Study Director: Stefan Hemmerich, PhD Y's Therapeutics, Inc.
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stefan Hemmerich, Clinical Operations, Y's Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT00876902     History of Changes
Other Study ID Numbers: YSPSL-0003-PF.3, IND 101,040
Study First Received: April 3, 2009
Last Updated: April 6, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Y's Therapeutics, Inc.:
liver transplantation
cadaveric liver transplantation
ischemic reperfusion injury
primary non-function
delayed non-Function
poor early graft function
YSPSL
recombinant PSGL-Ig

Additional relevant MeSH terms:
Radiation-Protective Agents
Protective Agents
Ischemia
Reperfusion Injury
Wounds and Injuries
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Krestin
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Interferon Inducers

ClinicalTrials.gov processed this record on September 14, 2014